[{"id":"dee45767-9e90-4e48-a60b-32ad585b3761","acronym":"","url":"https://clinicaltrials.gov/study/NCT05618041","created_at":"2022-11-16T19:57:24.637Z","updated_at":"2024-07-02T16:35:59.629Z","phase":"","brief_title":"The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies","source_id_and_acronym":"NCT05618041","lead_sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","biomarkers":" CD8 • IL6 • CD4 • IL10","pipe":"","alterations":" ","tags":["CD8 • IL6 • CD4 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • senl_BCMA"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 09/07/2022","start_date":" 09/07/2022","primary_txt":" Primary completion: 09/06/2024","primary_completion_date":" 09/06/2024","study_txt":" Completion: 12/06/2024","study_completion_date":" 12/06/2024","last_update_posted":"2022-12-06"},{"id":"adf97ffe-a5ab-4c9c-b219-b9ac297c59f3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04447573","created_at":"2021-01-18T21:24:04.628Z","updated_at":"2024-07-02T16:36:40.602Z","phase":"","brief_title":"Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma","source_id_and_acronym":"NCT04447573","lead_sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","biomarkers":" IFNG • IL6 • TNFA • IL10","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • S1904 • senl_BCMA"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/30/2020","start_date":" 06/30/2020","primary_txt":" Primary completion: 08/30/2022","primary_completion_date":" 08/30/2022","study_txt":" Completion: 12/30/2022","study_completion_date":" 12/30/2022","last_update_posted":"2020-09-29"}]